INO
Inovio Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.39
+1.84%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$143.21M
MomentumView details →
1D Return
+1.84%
YTD Return
−19.83%
RSI (14)
69.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$143.21M
RSI (14)
69.6
MomentumView details →
1D Return
+1.84%
YTD Return
−19.83%
SummaryUpdated Jun 1, 2026
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a biotechnology company founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania. The company went public in 1998 and has spent over four decades developing DNA-based medicines to treat diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Inovio is currently focused on advancing its lead product candidate INO-3107 toward commercialization, with plans to submit a Biologics License Application to the FDA in mid-2025 for treating recurrent respiratory papillomatosis, a rare HPV-related condition.
Similar companies
Latest newsMore news →
Inovio Pharmaceuticals reported first-half 2026 revenue of 1.137 billion yuan, up 55.5% year-over-year, with net profit attributable to shareholders of 246 million yuan versus a net loss of 30 million yuan in the first half of 2025.11d agoThe U.S. Food and Drug Administration completed several key steps in its review of Inovio Pharmaceuticals' biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis.23d ago